Can adjunctive therapies augment the efficacy of endovascular thrombolysis? A potential role for activated protein C

NEUROPHARMACOLOGY

卷:134

Review

Amar, Arun Paul^1,2,3  Sagare, Abhay P.^1,2  Zhao, Zhen^1,2  Wang, Yaoming^1,2  Nelson, Amy R.^1,2  Griffin, John H.^4,5  Zlokovic, Berislav V.^1,2 

[1] Univ Southern Calif, Keck Sch Med, Dept Physiol & Neurosci, Los Angeles, CA 90089 USA

[2] Univ Southern Calif, Keck Sch Med, Zilkha Neurogenet Inst, Los Angeles, CA 90089 USA

[3] Univ Southern Calif, Keck Sch Med, Dept Neurosurg, Los Angeles, CA USA

[4] Scripps Res Inst, Dept Mol Med, La Jolla, CA 92037 USA

[5] Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA

关键词: Activated protein C (APC);    Endovascular restorative neurosurgery;    Mechanical neurothrombectomy;    Neuroprotection;    Neurorestoration;    Stroke;    Thrombolysis;   

DOI  :  10.1016/j.neuropharm.2017.09.021

来源: Elsevier

【 摘 要 】

In the management of acute ischemic stroke, vessel recanalization correlates with functional status, mortality, cost, and other outcome measures. Thrombolysis with intravenous tissue plasminogen activator has many limitations that restrict its applicability, but recent advances in the development of mechanical thrombectomy devices as well as improved systems of stroke care have resulted in greater likelihood of vessel revascularization. Nonetheless, there remains substantial discrepancy between rates of recanalization and rates of favorable outcome. The poor neurological recovery among some stroke patients despite successful recanalization confirms the need for adjuvant pharmacological therapy for neuroprotection and/or neurorestoration. Prior clinical trials of such drugs may have failed due to the inability of the agent to access the ischemic tissue beyond the occluded artery. A protocol that couples revascularization with concurrent delivery of a neuroprotectant drug offers the potential to enhance the benefit of thrombolysis. Analogs of activated protein C (APC) exert pleiotropic anti-inflammatory, anti-apoptotic, antithrombotic, cytoprotective, and neuroregenerative effects in ischemic stroke and thus appear to be promising candidates for this novel approach. A multicenter, prospective, double-blinded, dose-escalation Phase 2 randomized clinical trial has enrolled 110 patients to assess the safety, pharmacokinetics, and efficacy of human recombinant 3K3A-APC following endovascular thrombolysis. This article is part of the Special Issue entitled 'Cerebral Ischemia'. (C) 2017 Elsevier Ltd. All rights reserved.

【 授权许可】

Free